<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37803436</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1746-1596</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>Diagnostic pathology</Title><ISOAbbreviation>Diagn Pathol</ISOAbbreviation></Journal><ArticleTitle>Possible Concomitant Aggressive NK Cell Leukemia and EBV-positive T-cell lymphoma; Using the online beta version of WHO-HAEM5 and videoconferencing software to make diagnoses accessible in an emerging economy.</ArticleTitle><Pagination><StartPage>111</StartPage><MedlinePgn>111</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">111</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13000-023-01395-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Using the World Health Organization Classification 5th edition (beta version online; WHO-HAEM5bv) in emerging economies is key to global healthcare equity. Although there may be ongoing updates, hesitancy in accepting and reporting these diagnoses in publication conflicts with the WHO's commitment to global accessibility. Aggressive NK cell leukemia (ANKL) and systemic EBV-positive T-cell lymphoma of childhood (SEBVTCL) with CD4-positive immunophenotype are both rare entities, are most described in Asians and East Asians, are associated with prior systemic chronic active EBV disease (CAEBV), and presentation with Hemophagocytic Lymphohistiocytosis (HLH). Recognizing and diagnosing any one of these entities requires not only training and experience in hematopathology, but good cooperation between clinical physicians and all areas of the laboratory. We describe a 30-year-old woman who presented to a Vietnam hospital and was rapidly diagnosed with ANKL, SEBVTCL, and HLH using WHO-HAEM5bv essential criteria, aided by expert consultation from a United States (US) board certified hematopathologist in real-time using video conferencing software.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Zoom&#x2122; videoconferencing software; Immunohistochemistry; flow cytometric immunophenotyping; polymerase chain reaction (PCR), Next Generation Sequencing (NGS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At the time of hospital admission, automated complete blood count (CBC) with differential count showed slight anemia, slight lymphocytosis, and moderate thrombocytopenia. HIV serology was negative. Whole blood PCR for EBV was positive showing 98,000 copies/ml. A lymph node biopsy revealed histology and immunohistochemistry consistent with the online beta version WHO-HAEM5 classification of SEBVTCL arising in CAEBV. Blood and bone marrow studies performed for staging revealed no histologic or immunohistochemical evidence of T-cell lymphoma in the bone marrow core, however, atypical blood smear lymphocyte morphology and blood immunophenotyping by flow cytometry were consistent with WHO-HAEM5 classification of ANKL. NGS revealed no evidence of genetic variant(s) associated with HLH in Vietnam. All laboratory studies were performed at Blood Transfusion Hematology Hospital (BTHH) in Ho Chi Minh City Vietnam.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although Vietnam, an emerging economy, currently lacks the laboratory infrastructure to more rigorously confirm a rare synchronous presentation of two distinct EBV-driven T/NK cell neoplasms, these two concomitant diagnoses were made using only laboratory techniques available in Vietnam with the help of WHO-HAEM5bv and real-time video consultation by a US hematopathologist.</AbstractText><CopyrightInformation>&#xa9; 2023. BioMed Central Ltd., part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dayton</LastName><ForeName>Vanessa J</ForeName><Initials>VJ</Initials><AffiliationInfo><Affiliation>Laboratory Medicine and Pathology, Hennepin County Medical Center, Minneapolis, MN, USA. vanessa.dayton@hcmed.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoang Thien</LastName><ForeName>Dang</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Blood Transfusion Hematology Hospital, Ho Chi Minh City, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xinh</LastName><ForeName>Phan Thi</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Blood Transfusion Hematology Hospital, Ho Chi Minh City, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arries</LastName><ForeName>Cade</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory Medicine and Pathology, University of Minnesota Medical Center-Fairview and University of Minnesota Medical School, Hematopathology, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sang</LastName><ForeName>Nguyen Ngoc</ForeName><Initials>NN</Initials><AffiliationInfo><Affiliation>Blood Transfusion Hematology Hospital, Ho Chi Minh City, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linh</LastName><ForeName>Ngo Ngoc Ngan</ForeName><Initials>NNN</Initials><AffiliationInfo><Affiliation>Blood Transfusion Hematology Hospital, Ho Chi Minh City, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lien</LastName><ForeName>Nguyen Phuong</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Blood Transfusion Hematology Hospital, Ho Chi Minh City, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dung</LastName><ForeName>Phu Chi</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Blood Transfusion Hematology Hospital, Ho Chi Minh City, Vietnam.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Diagn Pathol</MedlineTA><NlmUniqueID>101251558</NlmUniqueID><ISSNLinking>1746-1596</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054066" MajorTopicYN="Y">Leukemia, Large Granular Lymphocytic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="Y">Epstein-Barr Virus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016399" MajorTopicYN="Y">Lymphoma, T-Cell</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001853" MajorTopicYN="N">Bone Marrow</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051359" MajorTopicYN="Y">Lymphohistiocytosis, Hemophagocytic</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016411" MajorTopicYN="Y">Lymphoma, T-Cell, Peripheral</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aggressive NK Cell leukemia, chronic active EBV disease</Keyword><Keyword MajorTopicYN="N">Diagnostic hematopathology in emerging economies</Keyword><Keyword MajorTopicYN="N">Hemophagocytic lymphohistiocytosis, UNC13D</Keyword><Keyword MajorTopicYN="N">Systemic EBV-positive T-cell lymphoma of Childhood</Keyword><Keyword MajorTopicYN="N">Telepathology</Keyword><Keyword MajorTopicYN="N">WHO-HAEM5 classification (beta version online)</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>7</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>6</Day><Hour>23</Hour><Minute>47</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37803436</ArticleId><ArticleId IdType="pmc">PMC10557268</ArticleId><ArticleId IdType="doi">10.1186/s13000-023-01395-9</ArticleId><ArticleId IdType="pii">10.1186/s13000-023-01395-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2023 Jun 4]. (WHO classification of tumours series, 5th ed; vol 11). [Internet; beta version ahead of print] Available from: https://tumourclassification.iarc.who.int/chapters/63.</Citation></Reference><Reference><Citation>Suzuki R, Ott G, Takeuchi K et al. Aggressive NK cell Leukemia. In: WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2023 Jun 4]. (WHO classification of tumours series, 5th ed; vol 11). [Internet; beta version ahead of print] Available from: https://tumourclassification.iarc.who.int/chapters/63.</Citation></Reference><Reference><Citation>Chng WJ, Wood BL. EBV-positive T-cell and NK-cell lymphoid proliferations and lymphomas of childhood. In: WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2023 Jun 4]. (WHO classification of tumours series, 5th ed; vol 11). [Internet; beta version ahead of print] Available from: https://tumourclassification.iarc.who.int/chapters/63.</Citation></Reference><Reference><Citation>Araujo I, Sangueza OP, Kimura H, Liu W-P. Systemic chronic active EBV disease. In: WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2023 Jun 4]. (WHO classification of tumours series, 5th ed; vol 11). [Internet; beta version ahead of print] Available from: https://tumourclassification.iarc.who.int/chapters/63.</Citation></Reference><Reference><Citation>Marcogliese N, Sangueza JM, Ng S-B et al. Systemic EBV-positive T-cell lymphoma of childhood. In: WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2023 Jun 4]. (WHO classification of tumours series, 5th ed; vol 11). [Internet; beta version ahead of print] Available from: https://tumourclassification.iarc.who.int/chapters/63.</Citation></Reference><Reference><Citation>Xinh PT, Chuong HQ, Diem TPH, Nguyen TM, et al. Spectrum mutations of PRF1, UNC13D, STX11, and STXBP2 genes in vietnamese patients with hemophagocytic lymphohistiocytosis. Int J Lab Hematol. 2021;43:1524&#x2013;30. doi: 10.1111/ijlh.13674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijlh.13674</ArticleId><ArticleId IdType="pubmed">34339548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon Y-K, Kim WS, Lim ST, Kim SJ, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia lymphoma study group. Blood. 2012;120(15):2973&#x2013;80. doi: 10.1182/blood-2012-05-431460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-05-431460</ArticleId><ArticleId IdType="pubmed">22919026</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayton VJ, Nguyen CK, Van TT, Nguyen VT, et al. Evaluation of opportunities to improve hematopathology diagnosis for Vietnam pathologists. Am J Clin Path. 2017;148(6):529&#x2013;37. doi: 10.1093/ajcp/aqx108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcp/aqx108</ArticleId><ArticleId IdType="pubmed">29140404</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitkovski T, Bhuiya T, Esposito M. Utility of telepathology as a consultation tool between an off-site surgical pathology suite and affiliated hospitals in the frozen section diagnosis of lung neoplasms. J Pathol Inform. 2015;1:55&#x2013;9. doi: 10.4103/2153-3539.168515.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2153-3539.168515</ArticleId><ArticleId IdType="pmc">PMC4639948</ArticleId><ArticleId IdType="pubmed">26605120</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss SE, Tosata G, Armstrong G, Lawley T, et al. Ann Int Med. 1985;102:7&#x2013;16. doi: 10.7326/0003-4819-102-1-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-102-1-7</ArticleId><ArticleId IdType="pubmed">2578268</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikuta H, Taguchi Y, Tomizawa K, Kojima K, et al. Epstein-Barr virus genome-positive T-lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like illness. Nature. 1988;333(2):455&#x2013;7. doi: 10.1038/333455a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/333455a0</ArticleId><ArticleId IdType="pubmed">2836734</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara S, Tawa A, Yumura-Yagik, Murata M, et al. Cloncal T-cell lymphoproliferation containing Epstein-Barr (EB) virus DNA in a patient with chronic active EB virus infection. Japan J Cancer Res. 1989;80:99&#x2013;101. doi: 10.1111/j.1349-7006.1989.tb02273.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1349-7006.1989.tb02273.x</ArticleId><ArticleId IdType="pmc">PMC5917706</ArticleId><ArticleId IdType="pubmed">2542204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanegana H, Bhatia K, Gutierrez M, Kaneda H, et al. A syndrome of peripheral blood T-cell infection with Epstein-Barr virus (EBV) followed by EBV-positive T-cell lymphoma. Blood. 1998;91(6):2085&#x2013;91. doi: 10.1182/blood.V91.6.2085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V91.6.2085</ArticleId><ArticleId IdType="pubmed">9490694</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JI, Jaffe ES, Dale JK, Pittaluga S, et al. Characterization and treatment of chronic active Epstein-Barr virus in the United States. Blood. 2011;117(22):5835&#x2013;49. doi: 10.1182/blood-2010-11-316745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-11-316745</ArticleId><ArticleId IdType="pmc">PMC3112034</ArticleId><ArticleId IdType="pubmed">21454450</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintanilla-Martinez L, Ko Y-H, Kimura H, Jaffe ES. EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris HL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. International Agency for Research on Cancer; Lyon, France; 2017. Revised 4th Edition.</Citation></Reference><Reference><Citation>Smith MC, Cohen DN, Grieg B, Yenamandra A, et al. The ambiguous boundary between EBV-related hematophagocytic lymphohistiocytosis and systemic EBV-driven T cell lymphoproliferative disorder. Int J Exp Pathol. 2014;7(9):5738&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4203186</ArticleId><ArticleId IdType="pubmed">25337215</ArticleId></ArticleIdList></Reference><Reference><Citation>Yones I, Sakashita C, Imadome K-I, Kobyashi T, et al. Nationwide survey of chronic active EBV infection in Japan in accordance with the new WHO classification. Blood Adv. 2020;4(13):2918&#x2013;26. doi: 10.1182/bloodadvances.2020001451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020001451</ArticleId><ArticleId IdType="pmc">PMC7362364</ArticleId><ArticleId IdType="pubmed">32598475</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto A, Ishida F, Izutsu K, Yamasaki S. Allogeneic stem cell transplants for patients with aggressive NK-cell leukemia. Bone Marrow Transplant. 2021;56:347&#x2013;56. doi: 10.1038/s41409-020-01009-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41409-020-01009-8</ArticleId><ArticleId IdType="pubmed">32778688</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamadani M, Kanate AS, DiGillio A, Ahn KW, et al. Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia; a CIBMTR analysis. Biol Blood Marrow Transplantation. 2017;23(5):853&#x2013;6. doi: 10.1016/j.bbmt.2017.01.082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2017.01.082</ArticleId><ArticleId IdType="pmc">PMC5410937</ArticleId><ArticleId IdType="pubmed">28161608</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>